When The Regulator Moves Faster Than The Industry It Regulates

InnovationWhen The Regulator Moves Faster Than The Industry It RegulatesByNagesh Nama,Forbes Councils Member.for Forbes Technology CouncilCOUNCIL POSTExpertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. | Membership (fee-based)Jun 12, 2026, 07:30am EDTNagesh Nama, CEO, xLM. Nagesh Nama is a seasoned technology executive with over 30 years of experience in life sciences. getty​Something remarkable happened at a government press conference on April 28, 2026. The FDA—an agency more commonly associated with slow-moving bureaucracy—announced that it had conducted the first real-time clinical trial. This is an actual functioning program, with two of the world's largest pharmaceutical companies already streaming live clinical data directly into FDA review systems through a cloud platform powered by AI.Let that land for a moment. The federal regulator has outrun the industry it oversees.The FDA's announcement described a direct, AI-enabled, cloud-based data feed from active drug trials, meaning FDA scientists can now observe patient safety signals in near-real time rather than waiting months or years for data to move through the traditional chain. AstraZeneca and Amgen are already on board.This is a 60-year paradigm being retired.But the real story—the one that should keep every life sciences executive up at night—isn't the technology itself. It's the speed at which a government agency achieved transformation that the private sector has repeatedly failed to replicate. And the number that tells that story is this: According to FDA CAIO Jeremy Walsh, "About 1% of the agency’s workforce regularly used generative AI in their jobs." By April 2026, that number had crossed 80%. The agency accomplished this with a reduced workforce, no additional budget and ahead of its own deadlines.​The tool at the center of this story is Elsa, the FDA's LLM-powered generative AI assistant. Elsa allows FDA s...